1SXP.F • XETRA
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 1SXP.F in your mock portfolio yet.
With EPS of €0.97 and a PE ratio of 14.66, SCHOTT Pharma AG & Co. KGaA appears reasonably valued relative to earnings, suggesting neither clear overvaluation nor deep value. However, with no multi-year revenue, margin, or cash-flow data provided, it is difficult to confirm the durability of earnings or growth momentum. Overall, the financial snapshot looks adequate but not compelling enough on its own to offset current stock price weakness.
The stock trades at €14.22, down 7.4% over the past month and significantly below its 200-day moving average of €21.75, signaling a pronounced downtrend. An RSI of 32.25 is close to oversold territory, indicating selling pressure has been strong, though a short-term technical bounce is possible. Overall, the technical setup points to a weak trend and negative sentiment, despite some potential for near-term mean reversion.
Estimated monthly web traffic of 27,473 visitors is modest for a listed company, and social media follower growth is largely flat to slightly positive, with no sign of strong acceleration in digital engagement. LinkedIn stands out with 59,605 followers, consistent with a B2B, pharma/industrial profile, but growth rates across platforms are minimal. Overall, alternative data do not currently signal a strong inflection in brand interest or commercial momentum, but they also do not indicate deterioration.
Taken together, SCHOTT Pharma AG & Co. KGaA’s current setup leans bearish, driven mainly by a pronounced technical downtrend and recent price weakness. Fundamentals, as far as can be inferred from the limited EPS and PE data, appear reasonable but not strong enough to counteract negative price action. Alternative data are largely neutral, showing no strong surge in interest that might foreshadow a near-term re-rating.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: